Published · Aurelis Peptides
Keep “DAC” and “no DAC” in the name when comparing CJC-related entries. Shortening both to CJC-1295 removes a distinction that your material specification needs to resolve. Ask for the full peptide identity and any chemical modifications rather than treating a familiar search term as a complete description.
Aurelis lists Ipamorelin + CJC (no DAC) as Specification on request. This is a blend enquiry, not a confirmed standalone CJC-1295 DAC listing. The amount of each component and the complete formulation remain to be supplied.
What does the long-acting CJC-1295 research describe?
A 2006 study by Teichman and colleagues examined a long-acting analogue of growth hormone-releasing hormone in healthy adults. Its measurements included growth hormone, IGF-I and pharmacokinetic parameters. Read the primary CJC-1295 study.
A separate paper by Ionescu and Frohman describes the studied CJC-1295 analogue as binding to endogenous albumin, a protein in blood, and examines growth-hormone secretion patterns. Read the albumin-binding research. The studied molecular form matters when reading that literature; these papers do not test an Aurelis blend.
DAC vs no DAC: which fields should you compare?
| Field | DAC enquiry | No DAC enquiry |
|---|---|---|
| Full identity | Request complete sequence and modification details | Request complete sequence and modification details |
| Albumin-binding modification | Ask what the named designation identifies | Confirm what is absent and how the identity is documented |
| Research comparison | Match the offered identity to the actual studied form | Do not transfer findings from a differently modified form |
| Aurelis catalogue scope | No standalone DAC entry established by this page | Ipamorelin + CJC (no DAC), specification on request |
The table supplies enquiry questions, not a chemical specification for an unverified material. A label using “no DAC” does not supply the complete sequence or establish equivalence to every other product using similar wording. Record the exact identity accepted for your enquiry.
Why a blend needs two component specifications
The name Ipamorelin + CJC (no DAC) identifies a combined presentation. Ask for the full name and amount of both components, the total content and the reporting basis. Keep those fields beside the catalogue name so a missing second component does not disappear into a single total.
Aurelis keeps this entry unresolved because the existing source does not establish its complete formulation. Do not assign a ratio, total amount or concentration from another supplier's product. The blend guide explains the current listed combinations and their open specification questions.
Keep content separate from biological timing
A milligram amount identifies listed content on its stated basis. It does not establish how long a material acts, a liquid concentration or an amount delivered by a device. Related names may also refer to different molecular forms, making a comparison of totals alone misleading.
Use the content vs concentration guide for units, and request matching identity and content records through our quality-documentation page. Preserve the units as supplied and ask for clarification if the reporting basis changes.
Choose the presentation after clarifying the blend
Include a preferred vial or pen-style kit format in your enquiry. Confirm which presentation is offered for the exact accepted blend specification. A device image does not establish its contents or the identity of either component.
Request the component list for any proposed kit and keep packaging details separate from material identity. For a vial presentation, confirm the unit count and accepted content basis. This keeps format options reviewable without supplying use instructions.
Send the complete name with your enquiry
Use Ipamorelin + CJC (no DAC), identify the requested quantity and add your destination in the USA, Canada or Australia. Ask for the full component identities, amounts, total-content basis, available presentation and confirmation of current local availability.
Contact Aurelis Peptides or email sales@aurelispeptides.com. The response should make the offered formulation clear before a short name becomes an accepted specification.